Chromosomal translocations that generate in-frame oncogenic gene fusions are notable examples of the success of targeted cancer therapies.
Gene fusions of FGFR3-TACC3 ( F3–T3 ) had been previously described in 3% of human glioblastoma cases.
Subsequent studies have reported similar frequencies of F3–T3 in many other cancers, indicating that F3–T3 is a commonly occuring fusion across all tumour types.
F3–T3 fusions are potent oncogenes that confer sensitivity to FGFR inhibitors, but the downstream oncogenic signalling pathways remain unknown.
Researchers have now shown that human tumours with F3–T3 fusions cluster within transcriptional subgroups that are characterized by the activation of mitochondrial functions.
F3–T3 activates oxidative phosphorylation and mitochondrial biogenesis and induces sensitivity to inhibitors of oxidative metabolism. Phosphorylation of the phosphopeptide PIN4 is an intermediate step in the signalling pathway of the activation of mitochondrial metabolism.
The F3–T3–PIN4 axis triggers the biogenesis of peroxisomes and the synthesis of new proteins. The anabolic response converges on the PGC1alpha coactivator through the production of intracellular reactive oxygen species, which enables mitochondrial respiration and tumour growth.
These data illustrate the oncogenic circuit engaged by F3–T3 and show that F3–T3-positive tumours rely on mitochondrial respiration, highlighting this pathway as a therapeutic opportunity for the treatment of tumours with F3–T3 fusions.
Researchers have also provided insights into the genetic alterations that initiate the chain of metabolic responses that drive mitochondrial metabolism in cancer. ( Xagena )
Source: Nature, 2018